BioCardia (NASDAQ:BCDA) Shares Climb 1% – Still a Buy?

BioCardia, Inc. (NASDAQ:BCDA)’s share price was up 1% on Thursday. The company traded as high as $1.0450 and last traded at $1.02. 205,872 shares were traded during mid-day trading, a decline of 43% from the average session volume of 358,596 shares. The stock had previously closed at $1.01.

Wall Street Analyst Weigh In

BCDA has been the subject of several research reports. Zacks Research upgraded BioCardia from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of BioCardia in a research report on Monday, August 24th. Finally, Wall Street Zen raised BioCardia from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $25.00.

BioCardia Stock Performance

The firm’s 50 day moving average is $1.02 and its 200-day moving average is $1.04. The company has a market cap of $15.44 million, a PE ratio of -1.59 and a beta of 0.62.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. On average, analysts predict that BioCardia, Inc. will post -0.71 EPS for the current year.

About BioCardia

BioCardia, Inc is a biotechnology company developing regenerative medicine therapies for cardiovascular diseases. The company focuses on cell-based treatments intended to repair or improve damaged heart tissue and restore cardiac function in patients with serious cardiovascular conditions.

BioCardia’s portfolio includes the investigational CardiAMP Cell Therapy System, which uses a patient’s own bone marrow-derived cells and is being evaluated for conditions such as ischemic heart failure and chronic myocardial ischemia.